JPMorgan raised the firm’s price target on HealthEquity (HQY) to $129 from $126 and keeps an Overweight rating on the shares following the Q3 report. The says artificial intelligence is helping the company’s margins.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity’s Strategic Growth and Market Position Justify Buy Rating
- Healthequity’s Strong Performance and Growth Prospects Justify Buy Rating
- HealthEquity price target raised to $122 from $117 at Citizens JMP
- HealthEquity Inc. Reports Strong Q3 Financial Performance
- HealthEquity raises FY26 EPS view to $3.87-$3.95 from $3.74-$3.91